The latest headlines across every section, pulled from official and open-access sources.
On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).
The American Diabetes Association Applauds the Preservation of Medicaid Coverage for FDA-Approved Obesity Medications in North Carolina mcarmody Fri, 07/24/2026 - 17:52 Advocacy News The American Diabetes Association Applauds the Preservation of Medicaid Coverage for FDA-Approved Obesity Medications in North Carolina Arlington, VA July 24, 2026 The American Diabetes Association ® (ADA) recognizes North Carolina’s action to preserve Medicaid coverage for U.S. Food and Drug Administration (FDA)-approved weight-management medications, safeguarding access to evidence-based care for…
Multiple factors could get in the way of confirming a new commissioner before the midterm elections, experts said, leaving the agency’s long-term initiatives in limbo.
FDA Novel Drug Therapy Approvals for 2026
Priority Health partnered with Color Health and Grail to offer self-funded employers virtual cancer navigation, support and multi-cancer early detection beginning in 2027. The post Priority Health Launches 2 Cancer Support Solutions with Color Health, Grail appeared first on MedCity News .
The American Diabetes Association Announces the Fifth Annual Kiss a Pig Gala in New Orleans mcarmody Fri, 07/24/2026 - 15:47 Local Press Release The American Diabetes Association Announces the Fifth Annual Kiss a Pig Gala in New Orleans New Orleans, LA July 24, 2026 Top fundraiser earns the honor of kissing a pig, celebrating the history of insulin treatment The American Diabetes Association ® (ADA) is proud to once again host the Kiss a Pig Gala in New Orleans on July 25, bringing together local business leaders, advocates and supporters for an evening dedicated to advancing the fight to end…
Amgen has laid off around 40 employees as part of “organizational changes” meant to better align operations with the company’s strategic objectives, Fierce has learned.
An analyst said Saccaro’s decision was “surprising,” adding that investors were not calling for his departure.
An upcoming Medicare coverage decision for transcatheter aortic valve replacement devices and study readout for patients with moderate disease are expected to help the company maintain its momentum.
Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities (NDSRIs); Updated Information
Dr. Ankeet Bhatt interviews Dr. Nihar Desai on key terminology for albuminuria and discuss CV conditions associated with UACR as a biomarker.
Guidance for health professionals delivering the time-limited MenB vaccination offer on the eligible cohort.
On July 24, FDA approved Tylenol with Naproxen (acetaminophen 325 mg/naproxen sodium 110 mg tablets), the first fixed-dose combination product to pair acetaminophen with naproxen sodium in a single combination tablet for up to 12 hours of pain relief.
We’re about to enter a world beyond just talking to a chat tool about your health. AI tools are on the precipice of being able to take action on their advice. The post AI Will Reshape the Patient Experience appeared first on MedCity News .
The question is no longer whether healthcare innovation is accelerating. The question is where investors gain access to generate the strongest returns. The post Healthcare’s Next Source of Alpha Is Moving Upstream appeared first on MedCity News .
FDA Accepts First In Silico Drug Development Tool Under ISTAND Program to Help Predict Drug-Induced Liver Injury
M15 General Principles for Model-Informed Drug Development
This draft guidance provides drug developers with a validation framework and general recommendations for using new approach methodologies (NAMs) in drug development.
The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled “Monoclonal Antibodies: Streamlined Nonclinical Safety Studies.”
Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products
A new analysis of patients who took part in clinical trials for Kite Pharma’s CAR-T cell therapy Yescarta has revealed genetic signatures of toxicity risk, potentially providing a path forward for future CAR-Ts to be engineered to be safer.
Critical Path Innovation Meetings (CPIM)
The Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program is designed to expand DDT types by encouraging development of DDTs that are out of scope for existing DDT qualification programs but may still be beneficial for drug development.
The FDA is leading a transformative shift in drug safety evaluation—reducing, replacing or refining animal testing with advanced, human-relevant methods that better predict how medicines work in people.